OpenDNA has announced a new licensing agreement with Cleveland Clinic Innovations have completed an exclusive license agreement to commercialize Cleveland Clinic’s cutting-edge polygenic technology, which helps identify patients who could benefit most from intensive diabetes treatment. This collaboration builds on cutting-edge research developed at Cleveland Clinic and published in the American Diabetes Association journal Diabetes Care, which identifies individuals most likely to benefit from intensive type 2 diabetes therapy based on their genetic profile.
Through this agreement, OpenDNA will integrate Cleveland Clinic’s polygenic model into its own AI-powered genomic platform. The goal: to deliver a single, comprehensive test that not only assesses risk for cardiometabolic diseases and various cancers, but also identifies patients who are genetically more responsive to targeted diabetes interventions.
“We are honored to collaborate with Cleveland Clinic on this highly important technology, bringing improved care solutions to patients with type 2 diabetes,” said Eran Feldhay, CEO of OpenDNA.
By combining this innovative scoring method with OpenDNA’s existing platform, the partnership will offer clinicians a more complete picture of genetic risk and treatment responsiveness. This marks a new phase in translating genomics into actionable care pathways – particularly for chronic conditions like diabetes, where patient response to treatment can vary significantly.
“This agreement represents a step forward in enabling personalized care for patients with complex conditions like diabetes,” said Daniel Rotroff, PhD, Director of the Center for Quantitative Metabolic Research at Cleveland Clinic. Dr. Rotroff has an equity interest in OpenDNA. The partnership also reinforces OpenDNA’s commitment to advancing real-world applications of genomic science through meaningful collaborations with leading academic and clinical institutions. As the global burden of type 2 diabetes continues to rise, this technology represents a timely and clinically relevant tool that could help reduce complications and improve quality of life for millions.
